SGLT2 inhibitors may improve glycaemic control and renal markers without affecting body weight in patients with Prader-Willi syndrome and T2D, but they are tied to an elevated risk for adverse events.

The content creator pointed out out that in the US, an insulin can cost up to $1,000, while in Spain, it costs under $100.